×

CellRapeutics™ Serum from Tay-Sachs Disease Donor (XS-0426-XU200)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Sourced from donors of Tay-Sachs Disease, this serum reflects the metabolic disruption caused by Hexosaminidase A deficiency. The samples provide a unique proteomic and lipidomic window into lysosomal storage pathologies and the resulting neurodegenerative cascades. It is an invaluable resource for researchers developing enzymatic assays or screening for biomarkers related to ganglioside GM2 accumulation.

Specific Inquiry

  • Size:
  Add to Cart

Donor Information

  • Product Name
  • CellRapeutics™ Serum from Tay-Sachs Disease Donor
  • Cat. No.
  • XS-0426-XU200
  • Donor Age
  • Pediatric
  • Donor Health
  • Diagnosed with Tay-Sachs Disease. Serum reflects a severe lysosomal storage disorder, characterized by Hexosaminidase A deficiency and the resulting systemic metabolic imbalances.
  • Ethnicity
  • Predominantly Ashkenazi Jewish.
  • Anticoagulant
  • None (separated via centrifugation following natural coagulation).
  • Additional Donor Information
  • Each lot features serum from donors or carriers of Hexosaminidase A deficiency. Profiles focus on enzymatic activity levels and genetic variants for lysosomal storage disease studies.
  • Clinical Profile
  • Clinical form and Hexosaminidase A deficiency confirmation.

Additional Information

  • Medication History
  • Available upon request. Documentation of anticonvulsants and pharmacological interventions for symptom management and palliative care.
  • Formulation
  • Frozen
  • Cell Viability
  • Cell-free (no residual erythrocytes or leukocytes).
  • Mycoplasma Testing
  • Negative
  • Sterility Testing
  • Negative
  • Application
  • Drug Discovery, Immuno-oncology Research
  • Research Use Only
  • RUO
  • Quality Control
  • Each serum batch undergoes rigorous IRB-compliant screening, ensuring pathogen-free safety, consistent physicochemical properties, and standardized clinical characterization of disease-specific biomarkers to provide a reliable, high-purity biological matrix.
  • Storage
  • Store at -80°C or below for long-term stability, or at -20°C for up to 6 months, avoid repeated freeze-thaw cycles to preserve product quality.
  • Shiping
  • Dry Ice
  • Handling Notes
  • Thaw slowly on ice or at 4°C and centrifuge to remove cryoprecipitates, immediate aliquoting upon first thaw is recommended to maintain autoantibody functional integrity.
  • Warnings
  • Treat as potentially biohazardous human-derived material and handle strictly under BSL-2 guidelines using appropriate personal protective equipment.
  • Size
  • 1ML
  • Keywords
  • CellRapeutics™ Serum from Tay-Sachs Disease Donor, Serum, Tay-Sachs Disease

Case Studies

Customer Reviews and Q&As

There are currently no customer reviews or questions for CellRapeutics™ Serum from Tay-Sachs Disease Donor (XS-0426-XU200). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

Key Updates
Newsletter. (Creative Biolabs Authorized) NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution. (Creative Biolabs Authorized) NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
Novel Solution. (Creative Biolabs Authorized) NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
New Technology. (Creative Biolabs Authorized) NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.